StockpollyBeta
Get App
Popularity #3,150
CHRS · NASDAQ · Biotechnology

Coherus Oncology (CHRS)

Commercializes LOQTORZI while advancing mid-stage immuno-oncology antibodies.

$1.31
After hours+0.01 (+0.77%)
At close$1.30(−5.11%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue7592265715481012131214
Cost of revenue33851302134445554
Gross profit42713550204678810
747669565663495149544442
Research & development262628212221232526302121
Selling, general & administrative484940353541262623242321
Operating income−32−69−68−21−6−42−45−45−42−46−36−32
−8−1108−4−8−21−20−1−1
Interest expense101111555222222
Other non-operating income−20−3−13−130−30−2−1−1
Income before tax−40−80−68−13−11−51−47−45−45−46−37−33
Income tax expense000000000000
Net income from continuing operations−40−80−68−13−11−51−47−45−45−46−37−33
Discontinued operations00171000−9499−113
Net income−40−80103−13−11−51−57−41−35−37−38−21
EPS, basic−$0.41−$0.71$0.91−$0.11−$0.09−$0.44−$0.49−$0.39−$0.30−$0.31−$0.28−$0.13
EPS, diluted−$0.41−$0.71$0.82−$0.11−$0.09−$0.44−$0.49−$0.39−$0.30−$0.31−$0.28−$0.13
Weighted average shares, basic98111113115115115116116116120136155
Weighted average shares, diluted98111126115115115116116116120136155
EBITDA−28−68−63−6−4−44−44−42−41−43−34−30
Depreciation & amortization212121111111
EBIT−30−69−65−8−5−45−45−43−42−44−35−31